Dechra acquires veterinary marketing and distributions rights for Equine ProVet APC

ktay21/stock.adobe.com

Dechra Veterinary Products—a global specialist in veterinary pharmaceuticals and related products business—recently announced its acquisition of an exclusive license from Hassinger Biomedical for equine ProVet APC (Autologous Platelet Concentrate) and ProVet BMC (Bone Marrow Concentrate).

“ProVet APC has become the most highly sought-after regenerative system for equine athletes,” said Amy Hassinger, CEO of Hassinger Biomedical, in a company release. “We believe Dechra is especially poised through its experience in the veterinary sector to meet the growing global demand by veterinarians and their clients for the ProVet APC and BMC Regenerative Therapy System."

According to the release, the 2 patented medical devices concentrate platelets or bone marrow in 90 seconds with a processing time of 2.5 minutes from start to finish. The technology found within ProVet APC has been found to consistently deliver 6 to 8mls of a 7.8 higher concentration of platelet-rich plasma and can have a healing concentrate obtained from 54mls of whole blood in the 60ml system.

“The medical industry has long recognized that harnessing the growth factors found in platelets positively enhances healing results and reduces recovery time in soft tissue injuries,” said Mike Eldred, president of Dechra North America, in the release.

“These 2 products will be great additions to our equine product line and further strengthen our market position in veterinary regenerative medicine,” he continued.

Additionally, the acquisition of equine ProVet APC products will further accompany Dechra’s rthokine^® Vet IRAP joint therapy and offer veterinarians a comprehensive tool for their regenerative medicine needs.

To learn more about Dechra, go here.

References

Dechra Acquires Exclusive License from Hassinger Biomedical for Equine ProVet APC™. News release. Dechra Veterinary Products. September 22, 2021. Accessed September 27, 2021. [email].